Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical Trial of SEEG for Drug-resistant Epilepsy (SEEG-DRE)

3 november 2026 uppdaterad av: Beijing Pins Medical Co., Ltd

A Clinical Trial Evaluating the Safety and Efficacy of Stereoelectroencephalography (SEEG) Electrode Combined With Radiofrequency Lesion System for the Treatment of Drug-Resistant Epilepsy

This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy. It also assesses the safety and therapeutic effectiveness of SEEG-guided radiofrequency ablation for this patient group. The study will collect clinical evidence to support the standardized application of this combined diagnostic and treatment workflow for drug-resistant epilepsy.

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Detaljerad beskrivning

Stereoelectroencephalography (SEEG) is a minimally invasive presurgical evaluation modality for epilepsy. Intracranial electrodes are implanted using stereotactic techniques to record intracranial electroencephalographic (EEG) activity and deliver direct electrical stimulation, with the aim of delineating the epileptogenic zone in patients with focal epilepsy. Based on SEEG findings, clinicians can achieve highly precise localization of the epileptogenic zone and tailored surgical planning, or directly utilize SEEG-guided radiofrequency thermocoagulation (SEEG RF-TC) as an independent therapeutic intervention.

This study adopts a single-arm target-value design with a planned enrollment of 99 patients. All enrolled participants will undergo SEEG electrode implantation, followed by continuous SEEG monitoring for EEG recording and comprehensive presurgical evaluation. Eligible patients will then receive SEEG-guided radiofrequency thermocoagulation treatment. The primary efficacy endpoints include the success rate of intracranial EEG signal recording and the therapeutic response rate of thermocoagulation.

Studietyp

Interventionell

Inskrivning (Beräknad)

99

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Beijing, Kina, 100070
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100853
      • Beijing, Beijing Municipality, Kina, 100034
      • Beijing, Beijing Municipality, Kina, 100020
      • Beijing, Beijing Municipality, Kina, 100043
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Kina, 400037
        • Second Affiliated Hospital of Army Medical University
      • Chongqing, Chongqing Municipality, Kina, 400010
    • Fujian
      • Fuzhou, Fujian, Kina, 350004
        • First Affiliated Hospital of Fujian Medical University
        • Kontakt:
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510260
        • Zhujiang Hospital of Southern Medical University
        • Kontakt:
      • Guangzhou, Guangdong, Kina, 510623
        • Guangzhou women and children's medical center
        • Kontakt:
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • The Second Affiliated Hospital of Harbin Medical University
        • Kontakt:
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Tongji Hospital Affiliated to Tongji Medical College of HUST
        • Kontakt:
      • Wuhan, Hubei, Kina, 30014
        • Central Theater Command General Hospital of Chinese People's Liberation Army
        • Kontakt:
    • Hunan
      • Changsha, Hunan, Kina, 410028
        • Xiangya Hospital of Central South University
        • Kontakt:
    • Shandong
      • Jinan, Shandong, Kina, 250012
    • Xinjiang
      • Ürümqi, Xinjiang, Kina, 630000
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

2 år till 70 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Age ≥ 2 years old and ≤ 70 years old, of any sex;
  2. Prior confirmed diagnosis of drug-resistant epilepsy (DRE);
  3. Mean epilepsy seizure frequency ≥ 1 episode per month in the 3 months preceding screening;
  4. Patients scheduled to undergo stereoelectroencephalography (SEEG) recording and RF thermocoagulation (RF-TC);
  5. The subject or their legal representative is capable of understanding the trial purpose, demonstrates sufficient adherence to the study protocol, and has provided signed informed consent;

Exclusion Criteria:

  1. Patients with contraindications to MRI;
  2. Patients with coagulation dysfunction or known coagulopathy;
  3. Women who are pregnant, planning pregnancy within 6 months, or breastfeeding;
  4. Patients with known hypersensitivity to any electrode material;
  5. Patients with contraindications to neurosurgical procedures;
  6. Subjects who have participated in any other investigational drug or medical device clinical trial within 3 months preceding screening;
  7. Subjects with severe cardiac, hepatic, or renal impairment who, in the investigator's judgment, are unsuitable for participation in this clinical investigation;
  8. Subjects who, in the investigator's judgment, demonstrate poor compliance or are unable to complete the study as required;
  9. Any other condition that, in the investigator's opinion, would render the subject unsuitable for participation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: single arm

Participants in this trial will undergo SEEG electrode implantation followed by SEEG recording and mapping, and will complete SEEG radiofrequency thermocoagulation (RF-TC).

The patient will undergo SEEG-guided radiofrequency thermocoagulation (RF-TC). The procedure includes: electrode implantation, EEG recording, SEEG RF-TC, and electrode extraction.

Andra namn:
  • SEEG-guided radiofrequency thermocoagulation

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
SEEG Recording Success Rate
Tidsram: Within 30 days after implantation of electrodes

The proportion of patients achieving successful SEEG recording

Within 30 days after implantation of electrodes
RF-TC Efficacy Rate
Tidsram: Within 3 days after RF-TC

The proportion of patients achieving successful RF-TC.RF lesion measured on the post-procedural brain MRI.

Within 3 days after RF-TC

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Electrode Placement Accuracy
Tidsram: Within 30 days after implantation of electrodes

co-registering the pre-operative surgical plan and post-op CT,calculate the error between the actual placement position of the electrode and the surgical plan at the skull entry point and the target point.Measuring unit: mm.

Within 30 days after implantation of electrodes
Technical success rate of RF-TC
Tidsram: During RF-TC operation

Medical recording

During RF-TC operation
Vital signs-body temperature
Tidsram: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-pulse
Tidsram: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-respiratory rate
Tidsram: baseline, Perioperative

From medical recording

baseline, Perioperative
Vital signs-blood pressure
Tidsram: baseline, Perioperative

From medical recording

baseline, Perioperative
the reduction rate of spike frequency after RF-TC
Tidsram: Periprocedural of RF-TC

SEEG recording

Periprocedural of RF-TC
Questionnaire of Device Performance Evaluation
Tidsram: immediately after the procedure/surgery

a 5-level scale used to evaluate the Device Performance

immediately after the procedure/surgery
Seizure reduction rate
Tidsram: 90±7 days after RF-TC

Follow up

90±7 days after RF-TC
Mini-Mental State Examination (MMSE) score
Tidsram: Before and 90±7 days after RF-TC

Lower score indicates worse cognitive impairment

Before and 90±7 days after RF-TC
Quality of life in epilepsy-31 inventory (QOLIE-31) score
Tidsram: Before and 90±7 days after RF-TC

For adult; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC
Quality of life in epilepsy for Adolescents (QOLIE-AD-48) score
Tidsram: Before and 90±7 days after RF-TC

For Adolescents; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC
child epilepsy questionnnaire-parental form
Tidsram: Before and 90±7 days after RF-TC

For children; Higher scores correspond to better health-related quality of life

Before and 90±7 days after RF-TC

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of adverse events and serious adverse events
Tidsram: through study completion, an average of 5 months

Medical recording

through study completion, an average of 5 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

23 oktober 2026

Primärt slutförande (Beräknad)

30 juni 2027

Avslutad studie (Beräknad)

30 september 2027

Studieregistreringsdatum

Först inskickad

21 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

3 november 2026

Första postat (Faktisk)

6 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • SLXX(X)&PINS-C2-01-53

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera